---
title: "AbbVie gets FDA approval for antibiotic treatment Emblaveo"
date: "2025-02-07 21:57:42"
summary: "AbbVie (NYSE:ABBV) said it has received FDA approval for its intravenous antibiotic treatment Emblaveo. The FDA approved Emblaveo, a combination of aztreonam and avibactam, for use in combination with metronidazole for patients 18 years and older who have limited or no alternative options for the treatment of complicated intra-abdominal infections,..."
categories:
  - "seekalpha"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha"
menu: ""
thumbnail: "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2175801616/image_2175801616.jpg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

AbbVie (NYSE:[ABBV](https://seekingalpha.com/symbol/ABBV "AbbVie Inc.")) said it has received FDA approval for its intravenous antibiotic treatment Emblaveo.

The FDA approved Emblaveo, a combination of aztreonam and avibactam, for use in combination with metronidazole for patients 18 years and older who have limited or no alternative options for the treatment of complicated intra-abdominal infections, including those caused by certain susceptible Gram-negative microorganisms, [according to a statement](https://seekingalpha.com/pr/19995808-u-s-fda-approves-emblaveo-aztreonam-and-avibactam-for-the-treatment-of-adults-with).

The product will be available for commercial use in the U.S. in Q3 2025.

[seekalpha](https://seekingalpha.com/news/4405254-abbvie-gets-fda-approval-for-antibiotic-treatment-emblaveo)
